Genetic Platform Can Allow Some Meds to Be Repurposed for Obesity and Type 2 Diabetes

In the current project we developed genetically informed repurposed medications to tackle obesity and type 2 diabetes (T2D)

WeightControl.com Interview with:
Professor Murray Cairns. 
Sahar El Shair, PhD student
University of Newcastle, NSW, Australia

WeightControl.com:  What is the background for this study? 

Response: The background is that we want to improve global health by making a significant impact on chronic disease. Many of these complex disorders have a substantial genetic risk but this risk involves hundreds of genes (unlike the simple genetic disorders that people are more familiar with caused by a single gene) and manifests differently in different people.

To break through this problem we developed a platform for aggregating and scoring an individual’s risk for complex disorders in gene networks that can be modulated by drugs. This includes new drugs, existing drugs and those that are currently used for other conditions.